Neuroleptic malignant syndrome with the addition of aripiprazole to clozapine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 2, 2010, Pages 427-428

  Dassa, D ^a   Drai Moog, D ^a   Samuelian, J C ^a  

^a Department of Psychiatry Conception University Hospital 13005 ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; CREATINE KINASE; CREATININE; DIAZEPAM; LACTATE DEHYDROGENASE; OLANZAPINE; RISPERIDONE;

ADULT; ANAMNESIS; BLOOD PRESSURE; CASE REPORT; COMBINATION CHEMOTHERAPY; CONSTIPATION; DRUG DOSE INCREASE; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FEVER; HEMODYNAMICS; HUMAN; HYPERTHERMIA; INTENSIVE CARE; LETTER; LEUKOCYTE COUNT; MALE; MONOTHERAPY; NEUROLEPTIC MALIGNANT SYNDROME; PARANOID SCHIZOPHRENIA; SALIVATION; SEDATION; SINUS TACHYCARDIA;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG SYNERGISM; HUMANS; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PIPERAZINES; QUINOLONES;

EID: 77649275316     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.12.022     Document Type: Letter

References (14)

1. Ananth J., Parameswaran S., Gunatilake S., Burgoyne K., Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004, 65:464-470.
2. Barbui C., Signoretti A., Mule S., Boso M., Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment?. Schizophr Bull 2009, 35:458-468.
3. Burstein E.S., Wong J.M.S., Gao Y., Pham Y.E., Knapp A.E., Nash N.R., Olsson R., Davis R.E., et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-Desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 2005, 315:1278-1287.
4. Chang J.S., Ahn Y.M., Park H.J., Lee K.Y., Kim H., Kang U.G., et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008, 69:720-731.
5. Englisch S., Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prrg Neuro-Psychoph 2008, 32:1386-1392.
6. Goodwin G., Fleischhacker W., Arango C., Baumann P., Davidson M., de Hert M., et al. Advantages and disadvantages of combination treatment with antipsychotics. Eur Neuropsychopharmacol 2009, 19:520-532.
7. Haddad P.M., Dursun S.M. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008, 23:15-26.
8. Hasan S., Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998, 155:1113-1116.
9. Karunakaran K., Tungaraza T.E., Harborne G.C. Is clozapine aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia. J Psychopharmacol 2007, 21:543-544.
10. Pearlmann C.A. Neuroleptic malignant syndrome: a review of the literature. J Clin Psychoparmacol 1986, 6:257-273.
11. Rodriguez O.P., Dowell M.S. A case report of neuroleptic malignant syndrome without fever in a patient given aripiprazole. J Okla State Med Assoc 2006, 99:435-438.
12. Stahl S.M. Essential psychopharmacology 2004, 401-458. Cambridge University Press, New York. 2nd ed.
13. Strawm J.R. Aripiprazole and the neuroleptic malignant syndrome. Schizophr Res 2006, 85:298-299.
14. Trollor J.N., Chen X., Sachdev S. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009, 23:477-492.